Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.

Bonifacius A, Mausberg P, Floegel F, Dragon AC, Tischer-Zimmermann S, Stoll S, Rahmati P, Spieler P, Lammoglia Cobo MF, Halenius A, Abken H, Blasczyk R, Nerreter T, Hudecek M, Schambach A, Hansmann L, Maecker-Kolhoff B, Eiz-Vesper B

Open source

DOI
10.1016/j.omton.2026.201265
Published
2026 Sep 17
Container
Molecular therapy. Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.omton.2026.201265,
  title = {Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.},
  author = {Bonifacius A and Mausberg P and Floegel F and Dragon AC and Tischer-Zimmermann S and Stoll S and Rahmati P and Spieler P and Lammoglia Cobo MF and Halenius A and Abken H and Blasczyk R and Nerreter T and Hudecek M and Schambach A and Hansmann L and Maecker-Kolhoff B and Eiz-Vesper B},
  year = {2026},
  journal = {Molecular therapy. Oncology},
  doi = {10.1016/j.omton.2026.201265},
  url = {https://doi.org/10.1016/j.omton.2026.201265}
}

RIS

TY  - JOUR
TI  - Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.
AU  - Bonifacius A
AU  - Mausberg P
AU  - Floegel F
AU  - Dragon AC
AU  - Tischer-Zimmermann S
AU  - Stoll S
AU  - Rahmati P
AU  - Spieler P
AU  - Lammoglia Cobo MF
AU  - Halenius A
AU  - Abken H
AU  - Blasczyk R
AU  - Nerreter T
AU  - Hudecek M
AU  - Schambach A
AU  - Hansmann L
AU  - Maecker-Kolhoff B
AU  - Eiz-Vesper B
PY  - 2026
JO  - Molecular therapy. Oncology
DO  - 10.1016/j.omton.2026.201265
UR  - https://doi.org/10.1016/j.omton.2026.201265
ER  - 

APA

A, B., P, M., F, F., AC, D., S, T., S, S., P, R., P, S., MF, L. C., A, H., H, A., R, B., T, N., M, H., A, S., L, H., B, M., & B, E. (2026). Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.. Molecular therapy. Oncology. https://doi.org/10.1016/j.omton.2026.201265

Source records